Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer

被引：0
|
作者：
Sophie Broutin
Adam Stewart
Parames Thavasu
Angelo Paci
Jean-Michel Bidart
Udai Banerji
机构：
[1] Gustave Roussy,Département de Biologie et Pathologie Médicales
[2] Université Paris-Saclay,undefined
[3] Villejuif,undefined
[4] F-94805,undefined
[5] France,undefined
[6] The Institute of Cancer Research,undefined
[7] Clinical Pharmacology and Trials Team,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
drug combinations; NSCLC; KRAS mutant; MEK inhibitor; trametinib; m-TOR inhibitor; AZD2014;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：549 / 552
页数：3
相关论文
共 50 条
  • [41] Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
    Gao, Liyuan
    Shen, Weizhang
    FRONTIERS IN GENETICS, 2022, 13
  • [42] Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer
    Zhao, Zhuochen
    Wan, Junhu
    Guo, Manman
    Wang, Yangxia
    Yang, Zhengwu
    Zhou, Fuyou
    Li, Zhuofang
    Ming, Liang
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (01)
  • [43] Expression and Clinical Significance of Ezrin in Non-Small-Cell Lung Cancer
    Zhang, Xiao-Qin
    Chen, Guo-Ping
    Wu, Tao
    Yan, Jian-Ping
    Zhou, Jian-Ying
    CLINICAL LUNG CANCER, 2012, 13 (03) : 196 - 204
  • [44] Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer
    Carnaghi, C
    Rimassa, L
    Garassino, I
    Santoro, A
    ANNALS OF ONCOLOGY, 2001, 12 : S119 - S123
  • [45] Pulsatile MEK inhibition improves antitumor immunity and T-cell function in Kras mutant lung cancer
    Choi, Hyejin
    Deng, Jiehui
    Li, Shuai
    Silk, Tarik
    Brea, Elliott J.
    Boiarsky, Jonathan
    Akbay, Esra A.
    Smith, Paul D.
    Merghoub, Taha D.
    Wong, Kwok-Kin
    Wolchok, Jedd D.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [46] Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy
    Li, Shutong
    Wang, Aoxue
    Wu, Yongya
    He, Shengyuan
    Shuai, Wen
    Zhao, Min
    Zhu, Yumeng
    Hu, Xiuying
    Luo, Yubin
    Wang, Guan
    IMMUNOLOGICAL REVIEWS, 2024, 321 (01) : 300 - 334
  • [47] Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer-preliminary findings
    Pazik, Milena
    Michalska, Katarzyna
    Zebrowska-Nawrocka, Marta
    Zawadzka, Izabela
    Lochowski, Mariusz
    Balcerczak, Ewa
    BMC CANCER, 2021, 21 (01)
  • [48] Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment
    Linardou, Helena
    Kotoula, Vassiliki
    Kouvatseas, George
    Mountzios, Giannis
    Karavasilis, Vasilios
    Samantas, Epaminondas
    Kalogera-Fountzila, Anna
    Televantou, Despina
    Papadopoulou, Kyriaki
    Mavropoulou, Xanthipi
    Daskalaki, Emily
    Zaramboukas, Thomas
    Efstratiou, Ioannis
    Lampaki, Sofia
    Rallis, Grigorios
    Res, Eleni
    Syrigos, Konstantinos N.
    Kosmidis, Paris A.
    Pectasides, Dimitrios
    Fountzilas, George
    CANCER GENOMICS & PROTEOMICS, 2019, 16 (06) : 531 - 541
  • [49] Molecular profile of KRAS G12C-mutant non-small-cell lung cancer and colorectal cancer in Brazilian patients
    Souza, Bianca Mendes
    Leite, Laura Rabelo
    Parma, Sabrina A.
    Lopes, Natalia P.
    Malta, Frederico S.
    Araujo, Luiz Henrique
    Freire, Maira C.
    CANCER RESEARCH, 2020, 80 (16)
  • [50] MET/RON Inhibition in KRAS Mutated Non Small Cell Lung Cancer
    Tumuluru, Sravya
    Hasina, Rifat
    Alban, Juan
    Husain, Aliya
    Ferguson, Mark
    Vokes, Everett E.
    Salgia, Ravi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S452 - S453
12345